The partnership addressed complex peptide synthesis and purification challenges to achieve high yield and purity suitable for clinical use
BEVERLY HILLS, California—October 20, 2025. Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announced the development of a unique, cGMP-compliant manufacturing process. The program was executed in partnership with Syngene International Limited (“Syngene”), a leading integrated research, development, and manufacturing services organization.
QR-01 is an 37-amino acid (37-mer), cationic, amphipathic peptide designed to target and eliminate harmful bacteria, representing a potential treatment for advanced gum disease, or aggressive periodontitis. To advance QR-01 into clinical trials, Orocidin required the production of a peptide suitable for human use, with a target purity of greater than 99% and a single maximum impurity of less than 1%.
Orocidin has completed the first production of cGMP material that will allow Orocidin to initiate the first human pilot efficacy study in patients (a Phase IIA study).
Addressing the manufacturing challenge:
The development of this complex 37-mer peptide posed several technical challenges due to its chemical characteristics. Rich in hydrophobic and basic amino acids, QR-01 was prone to aggregation during Solid-Phase Peptide Synthesis (SPPS), resulting in incomplete coupling and low crude yield. The N-terminal region, containing multiple lysine and arginine residues, was susceptible to incomplete deprotection and side reactions. Additionally, the peptide exhibited poor solubility, high oxidation sensitivity, and a tendency to form aggregates during purification.
To overcome these challenges, a customized synthesis and purification process was developed in collaboration with Syngene’s chemical development team. A low-loading resin approach was implemented during SPPS to minimize sequence-induced aggregation, while optimization of the chemical cleavage step prevented the formation of TFA adducts. This refinement yielded a crude peptide purity greater than 50%. Improved solubility enabled smoother purification, and a tailored single-step reverse-phase HPLC purification process was established, resulting in a final peptide purity exceeding 99%, with a single maximum impurity of 0.4% and total impurities of 0.6%.
Seamless transition to cGMP manufacturing:
“We were very impressed with Syngene’s professionalism, commitment to scientific excellence, and ability to deliver high-quality work on time. This partnership work was the result of a strong and fruitful collaboration between Orocidin and Syngene by utilizing the highly skilled scientists and state-of-the-art facilities from Syngene to facilitate the development and progress of Orocidin’s QR-01,” said Allan Wehnert, CEO and Founder of Orocidin.
Following the successful completion of small-scale synthesis, the process was transitioned to cGMP manufacturing, achieving an overall yield of 10%. It demonstrated reproducibility and consistency in line with clinical requirements while highlighting Syngene’s role in developing scalable GMP peptide production methods.
About Orocidin:
Orocidin’s mission is to develop the preferred treatment against aggressive periodontitis. Our innovative therapeutic agent, QR-01, distinguishes itself through its unique ability to provide treatment of both inflammation and bacterial infection.
About Nordicus Partners Corporation:
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired 100% of Orocidin A/S, a Danish preclinical-stage biotech company developing next-generation therapies for periodontitis and 100% of Bio-Convert A/S, a Danish preclinical-stage biotech company dedicated to revolutionizing the treatment of oral leukoplakia. For more information about Nordicus, please visit: www.nordicuspartners.com, and follow us on LinkedIn, X, Threads and BlueSky.
Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue,” “confident” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition, prospects of being listed on Nasdaq and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
For further information, contact:
Mr. Henrik Rouf
Chief Executive Officer
Tel +1 310 666 0750
Kim T. Mücke is a Danish state authorized public accountant (authorization deposited in 2025). He was partner with Deloitte (Denmark) in the period 2002 to 2022 where he – among others – served as signing partner for various listed companies including companies that underwent IPO processes. In the years 2023-2024, Mr. Mücke was Head of Corporate Clients for BDO (Denmark). From 1 January 2025, Mr. Mücke has started as independent advisor,specialized in financial reporting, risk management and corporate governance. Mr. Mücke has a master’s degree in Auditing and Accounting from the Copenhagen Business School.
Elizabeth Addonizio is an experienced finance professional with twenty-five years of business and leadership experience. She is the founder of Fair Winds Capital LLC, AMN LLC, and GEDI LLC, through which she has spent the past decade investing, along with families and entrepreneurs, in U.S.-based, sector-agnostic, early-stage venture investments that prioritize impact and environmental, social, and good governance (ESG) principles by investing in companies’ Pre-seed to C-round capital raises. She has also served as a fractional CFO for many companies in diverse sectors.
Prior to her venture investing and CFO work, from 2012 to 2016, Ms. Addonizio was a founding managing director and investment professional at Cranemere, an international investment holding company and private equity firm structured to invest with a commitment to sustainability and ESG principles, along with other families, in middle market private companies (~$200mm-$500mm in enterprise value). While at Cranemere she sourced and evaluated dozens of investment opportunities, serving on the firm’s Investment Committee, and overseeing due diligence, financing, and other acquisition-related activities. Prior to joining Cranemere, from 2006 to 2012, Ms. Addonizio worked at Morgan Stanley in the Investment Banking and Corporate M&A and Strategy Divisions, advising on over $25 billion of mergers and acquisitions, leveraged finance, and equity transactions.
In addition to her work in finance, since 2004, Ms. Addonizio has served as an intelligence officer in the U.S. Navy Reserve. Currently, she is the board-selected Commanding Officer of the 30-member Navy Reserve Office of Naval Intelligence (ONI) Kennedy Maritime Analysis Center Unit in St. Louis, MO. Previously, she was Executive Officer of 110+-person Navy Reserve Joint Intelligence Operations Center Europe (JIOCEUR) Analytic Center Molesworth 0366 (located at Joint Reserve Intelligence Support Element Sheridan, Fort Sheridan, IL). Prior to this position, she served as the board-selected Executive Officer of 75-person ONI Navy Reserve Nimitz Unit at Fort Dix, NJ. She was also the Officer in Charge (OIC) of a twenty-eight-person Naval Criminal Investigative Service (NCIS) Unit based in New London, CT. Board-selected to hold this position, she was one of only three to have command of a unit at her rank in the Navy Reserve Intelligence Community, the first woman to ever serve in this NCIS unit, and by extension, the unit’s first female OIC. During her twenty years in the U.S. Navy, she has led numerous teams in support of JIOCEUR, ONI, NCIS, and the Defense Intelligence Agency (DIA). She also served 20 months of active military duty as an analyst on the personal staff of the Commander of U.S. Central Command, General David Petraeus.
Earlier in her career, Ms. Addonizio was elected to serve two terms as the 9th Ward Alderwoman in New Haven, Connecticut, serving as the Vice Chair of the Finance Committee with legislative oversight of the city’s $450 million annual budget. As a Henry Luce Scholar in China, she taught economics at Peking University and worked on China’s accession to the World Trade Organization at the World Bank Resident Mission. She has also worked in the U.S. National Security Council and in the Office of the U.S. Trade Representative. She holds a Ph.D. from Yale University, a M.P.A. from Princeton University, a B.A. from Bucknell University, and was a Fulbright Scholar in El Salvador. Ms. Addonizio is currently a member of the Association for Corporate Growth and the Alliance of Merger and Acquisitions Advisers. She is also a Council on Foreign Relations Life Member, a NationSwell Council Member, a Truman National Security Project Fellow, and a Yale World Fellow.